Ofer Haviv'un ücretlendirmesi Evogene'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$24m
Jun 30 2024	n/a	n/a	-US$20m
Mar 31 2024	n/a	n/a	-US$21m
Dec 31 2023	US$401k	US$390k	-US$24m
Sep 30 2023	n/a	n/a	-US$20m
Jun 30 2023	n/a	n/a	-US$23m
Mar 31 2023	n/a	n/a	-US$25m
Dec 31 2022	US$464k	US$415k	-US$27m
Sep 30 2022	n/a	n/a	-US$31m
Jun 30 2022	n/a	n/a	-US$32m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	US$530k	US$420k	-US$28m
Sep 30 2021	n/a	n/a	-US$29m
Jun 30 2021	n/a	n/a	-US$26m
Mar 31 2021	n/a	n/a	-US$24m
Dec 31 2020	US$592k	US$367k	-US$23m
Sep 30 2020	n/a	n/a	-US$21m
Jun 30 2020	n/a	n/a	-US$21m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	US$538k	US$366k	-US$18m
Sep 30 2019	n/a	n/a	-US$18m
Jun 30 2019	n/a	n/a	-US$18m
Mar 31 2019	n/a	n/a	-US$19m
Dec 31 2018	US$517k	US$324k	-US$21m

Tazminat ve Piyasa: Ofer 'nin toplam tazminatı ($USD 401.00K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 645.47K ).

Tazminat ve Kazançlar: Ofer 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Ofer Haviv (58 yo)

20.1yrs

Görev süresi

US$401,000

Tazminat

Mr. Ofer Haviv, CPA, served as Interim Chief Executive Officer of Lavie Bio Ltd. since January 2023. He has been Chief Executive Officer and President of Evogene Limited since December 2004 and served as i...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ofer Haviv	CEO & President	20.1yrs	US$401.00k	Veri yok
Brian Ember	Chief Executive Officer of AgPlenus Ltd	3.1yrs	US$456.00k	Veri yok
Elran Haber	Chief Executive Officer of Biomica Ltd	7yrs	US$339.00k	0% $ 0
Amit Noam	Chief Executive Officer of Lavie Bio Ltd.	1.8yrs	US$606.00k	Veri yok
Yaron Eldad	Chief Financial Officer	2.8yrs	Veri yok	0% $ 0
Rachel Gerber	Head of Investor Relations	1.6yrs	Veri yok	Veri yok
Liat Wejgman	Vice President of Human Resources	3yrs	Veri yok	Veri yok
Eyal Ronen	Executive Vice President of Business Development	2.6yrs	Veri yok	0% $ 0
Yoash Zohar	Chief Executive Officer of Casterra Ag Ltd.	less than a year	Veri yok	Veri yok
Dan Gelvan	Chief Executive Officer of Ag Plenus Ltd.	less than a year	Veri yok	Veri yok
Russ Putland	Vice President of Commercial of Lavie Bio Ltd.	no data	Veri yok	Veri yok

2.7yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: EVGN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Dan Falk	Independent Director	3.2yrs	Veri yok	0% $ 0
Nir Nimrodi	Independent Director	2.2yrs	Veri yok	0% $ 0
Leon Recanati	Independent Director	19.7yrs	Veri yok	1.23% $ 136.4k
Sarit Weiss-Firon	Independent Chairperson of the Board	8.4yrs	Veri yok	0% $ 0
Oded Shoseyov	Independent Director	6.2yrs	Veri yok	0% $ 0
Adrian Percy	Independent Director	5.9yrs	Veri yok	0% $ 0

6.0yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: EVGN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/10 05:00
Gün Sonu Hisse Fiyatı	2025/01/10 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Evogene Ltd. 8 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Scott Henry	Alliance Global Partners
Benjamin Haynor	Alliance Global Partners
Kristen Kluska	Cantor Fitzgerald & Co.

Evogene Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Evogene Ltd. Announces Executive Changes

Evogene Ltd., Annual General Meeting, Jun 06, 2024

Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024

Evogene Ltd., Annual General Meeting, May 11, 2023

Evogene Ltd., Annual General Meeting, Sep 08, 2022

Eyal Ronen Joins as Executive Vice President of Business Development of Evogene Ltd., Effective as of June 12, 2022

Recent updates

Evogene Ltd. to Report Q3, 2024 Results on Nov 21, 2024

Evogene Ltd. Announces Executive Changes

Evogene Ltd. to Report Q2, 2024 Results on Aug 22, 2024

Evogene Ltd. to Report Q1, 2024 Results on May 23, 2024

Evogene Ltd., Annual General Meeting, Jun 06, 2024

Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $7.3 million.

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Evogene Ltd. to Report Q4, 2023 Results on Mar 07, 2024

Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Evogene Ltd. to Report Q3, 2023 Results on Nov 15, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Evogene Ltd. to Report Q2, 2023 Results on Aug 17, 2023

Evogene Ltd 's ChemPass AI Tech-Engine is Introduces with New Breakthrough Machine Learning Technology for Target-Protein Discovery

Biomica Ltd. Reports Interim Positive Results from Pre-Clinical Studies in its IBS Program

New minor risk - Share price stability

Evogene Ltd., Annual General Meeting, May 11, 2023

Evogene Ltd. to Report Q1, 2023 Results on May 18, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$6.00

Evogene Ltd. to Report Q3, 2022 Results on Nov 17, 2022

Evogene unit files for EPA approval of bio-fungicide LAV.311 for fruit rots

Evogene unit launches 2nd-gen medical cannabis products in Israel

Lavie Bio appoints Guri Oron as CEO

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Evogene GAAP EPS of -$0.42 misses by $0.23, revenue of $0.55M beats by $0.33M

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Evogene regains compliance with Nasdaq's minimum bid price requirement

Evogen stock rises after unit gets $10M investment from ICL under collaboration agreement

Evogene Ltd., Annual General Meeting, Sep 08, 2022

Evogene Ltd. to Report Q2, 2022 Results on Aug 31, 2022

Eyal Ronen Joins as Executive Vice President of Business Development of Evogene Ltd., Effective as of June 12, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Evogene Ltd. to Report Q1, 2022 Results on May 26, 2022

Price target decreased to US$10.33

High number of new directors

Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus

Price target decreased to US$10.33

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Evogene: Computational Biology Technology Hub; Focus On Canonic (Medical Cannabis)

Evogene Ltd. to Report Q4, 2021 Results on Mar 10, 2022

High number of new directors

Evogene Ltd. Announces Executive Changes

Chief Executive Officer of AgPlenus Ltd. Douglas Eisner has left the company

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 3Q 2020)

High number of new and inexperienced directors

Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical Market

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.17 loss in 2Q 2020)

Evogene: Bullish With Canonic's Entry Into Israeli Medical Cannabis Markets

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 1Q 2020)

Evogene EPS beats by $0.01, beats on revenue

Full year 2020 earnings released: US$0.83 loss per share (vs US$0.70 loss in FY 2019)

Evogene Ltd. to Report Q4, 2020 Results on Mar 03, 2021

Price target raised to US$15.00

New 90-day high: US$7.68

New 90-day high: US$5.95

New 90-day high: US$5.63

Evogene unit - Canonic inks cultivation deal for medical cannabis varieties

AgPlenus reaches a 'Lead' Stage in its mode-of-action herbicide program

New 90-day high: US$4.31

Evogene: Q3 Update And Upcoming Catalysts

Third quarter 2020 earnings released: US$0.18 loss per share

Evogene Ltd. to Report Q3, 2020 Results on Nov 18, 2020

New 90-day high: US$4.16

New 90-day high: US$3.09